Novartis' Entresto flops heart failure trial, eroding $5B hopes by Kyle Blankenship Monday, July 29, 2019 Novartis envisioned $5 billion in peak sales for its cardiovascular drug Entresto, but, after a major trial flop, that goal appears out of reach.
ACC: Novartis' Ilaris cuts CV risks but fails to halt diabetes by Eric Sagonowsky Tuesday, March 13, 2018 Novartis' canakinumab, a rare disease med it's studying for the heart, cut CV risks in patients with diabetes and chronic kidney disease, data shows.
Chasing CV nod, Novartis unveils canakinumab subgroup data by Eric Sagonowsky Tuesday, November 14, 2017 Back in August, Novartis published findings from the phase 3 Cantos trial of Ilaris that weren't "fully compelling to payers."
Novartis faces uphill battle turning Ilaris into CV blockbuster by Arlene Weintraub Monday, August 28, 2017 Analysts were underwhelmed by Novartis' data on the potential for its anti-inflammatory drug Ilaris to reduce the risk of major cardiovascular events.
Novartis' Ilaris nets a trio of new rare-disease nods by Carly Helfand Monday, September 26, 2016 It’s been a while since Novartis’ rare disease med Ilaris picked up a label-expansion boost, but now the Swiss drugmaker has three of them to show for its efforts.
